Preserving Neurological Function in People at High and Low Risk of Aggressive Multiple Sclerosis: An Observational Cohort Study


Por: Roos, I, Sharmin, S, Ozakbas, S, Alroughani, R, Eichau, S, Grand'Maison, F, Boz, C, Lechner-Scott, J, Buzzard, K, Prat, A, Khoury, SJ, Grammond, P, van der Walt, A, Blanco, Y, Foschi, M, Soysal, A, Barnett, M, Prevost, J, Terzi, M, Gerlach, O, Macdonell, R, Sa, MJ, Spitaleri, D, Laureys, G, Van Pesch, V, John, N, Cartechini, E, Gouider, R, Maimone, D, Ramo-Tello, C, Hodgkinson, S, Slee, M, Mccombe, P, Garber, J, Sanchez-Menoyo, JL, Al-Asmi, A, Kermode, AG, Lapointe, E, Shaygannejad, V, Van Wijmeersch, B, Willekens, B, Castillo-Triviño, T, Taylor, B, Mathey, G, Le Page, E, De Seze, J, Ruet, A, Clavelou, P, Berger, E, Zephir, H, Kwiatkowski, A, Pelletier, J, Moreau, T, Labauge, P, Ciron, J, Lebrun-Frenay, C, Papeix, C, Defer, G, Laplaud, DA, Thouvenot, E, Stankoff, B, Maillart, E, Al-Khedr, A, Bourre, B, Casez, O, Dos Santos, A, Camdessanche, JP, Hankiewicz, K, Wahab, A, Cabre, P, Heinzlef, O, Pottier, C, Moulin, S, Magy, L, Labeyrie, C, Doghri, I, Vukusic, S and Kalincik, T

Publicada: 4 abr 2026 Ahead of Print: 1 abr 2026
Resumen:
Background and ObjectivesPatients aged >= 35 years at multiple sclerosis (MS) symptom onset with an Expanded Disability Status Scale (EDSS) score >= 3 within the first year are at highest risk of developing aggressive MS (EDSS >= 6 within 10 years). Patients without these features are at lowest risk. This study aimed to evaluate whether high-efficacy disease-modifying therapy (HE-DMT) reduced the risk of relapse and disability accumulation in individuals at high risk of aggressive MS, and whether treatment benefit varied by MS severity.MethodsThis observational cohort study used longitudinal data from two registries: MSBase (international) and OFSEP (France). Adults with relapse-onset MS and an EDSS score recorded within 12 months of symptom onset were included. Patients were classified into high-risk or low-risk groups for aggressive MS based on the above strata; those at intermediate risk were excluded. A pseudo-cohort framework compared periods of continuous HE-DMT (fingolimod, cladribine, monoclonal antibodies) with periods of non-HE-DMT states (on lower-efficacy DMTs or untreated) within each aggressive MS risk stratum. Marginal structural models with repeated adjustment for time-varying confounders of treatment and censoring were used to estimate counterfactual cumulative hazards of relapses and 6-month confirmed disability worsening and improvement. An interaction between MS risk stratum and treatment strategy was tested. A secondary analysis evaluated patients who received an HE-DMT during the study period.ResultsIn total, 10,405 people (2021 high risk, 8384 low risk) were included. Continuous HE-DMT reduced the risk of relapse in both high-risk and low-risk groups. There was no evidence of a difference in disability outcomes between treatment approaches. There was no evidence of an interaction between aggressive MS risk and treatment effect. In stratified analyses, lowest relapse risk was observed in the low-risk group treated with HE-DMT (hazard ratio [HR] 0.75, 95% CI 0.69-0.80). Treatment with HE-DMT was associated with relapse risk comparable to that observed in the low-risk group not treated with HE-DMT (HR 0.99, 0.87-1.13). In a secondary analysis restricted to patients who receive HE-DMT during the study timeframe, treatment with HE-DMT reduced the risk of disability worsening in the high-risk group (HR 0.75, 0.58-0.99), to the level observed in the low-risk group (HR 0.80, 0.70-0.92).ConclusionsHE-DMTs reduced the risk of relapse in people at both high and low risk of aggressive MS, with no evidence of differential treatment benefit. In the overall population, no evidence of a difference in disability outcomes between HE-DMT-treated and HE-DMT-untreated time was observed. However, among patients ever exposed to HE-DMT, disability worsening was less common while treated with HE-DMT.

Filiaciones:
Roos, I:
 Royal Melbourne Hosp, Neuroimmunol Ctr, Dept Neurol, L7 635 Elizabeth St, Melbourne, Vic 3000, Australia

 Univ Melbourne, Dept Med, CORE, Melbourne, Australia

Sharmin, S:
 Univ Melbourne, Dept Med, CORE, Melbourne, Australia

Ozakbas, S:
 Izmir Univ Econ, Med Point Hosp, Konak Izmir, Turkiye

 Multiple Sclerosis Res Assoc, Izmir, Turkiye

Alroughani, R:
 Amiri Hosp, Dept Med, Div Neurol, Sharq, Kuwait

Eichau, S:
 Hosp Univ Virgen Macarena, Dept Neurol, Seville 41004, Spain

Grand'Maison, F:
 Neuro Rive Sud, Greenfield Pk, PQ, Canada

Boz, C:
 KTU, Farabi Hosp, Fac Med, Dept Neurol, Trabzon, Turkiye

Lechner-Scott, J:
 Univ Newcastle, Hunter Med Res Inst, Newcastle, NSW, Australia

 John Hunter Hosp, Hunter New England Hlth, Newcastle, NSW, Australia

Buzzard, K:
 Box Hill Hosp, Dept Neurosci, Melbourne, Vic, Australia

 Monash Univ, Eastern Hlth Clin Sch, Box Hill, Australia

Prat, A:
 CHUM MS Ctr, Montreal, PQ, Canada

 Univ Montreal, Montreal, PQ, Canada

Khoury, SJ:
 Univ Montreal, Montreal, PQ, Canada

Grammond, P:
 Amer Univ Beirut, Med Ctr, Nehme & Therese Tohme Multiple Sclerosis Ctr, Beirut, Lebanon

van der Walt, A:
 CISSS ChaudiEre Appalache, Levis, PQ, Canada

 Alfred Hosp, Dept Neurol, Melbourne, Australia

Blanco, Y:
 Monash Univ, Sch Translat Med, Dept Neurosci, Melbourne, Australia

Foschi, M:
 Hosp Clin Barcelona, Ctr Neuroimmunol, Serv Neurol, Barcelona, Spain

 S Maria Croci Hosp Ravenna, Dept Neurosci, Neurol Unit, MS Ctr, Ravenna, Italy

Soysal, A:
 Univ Aquila, Dept Biotechnol & Appl Clin Sci, Laquila, Italy

Barnett, M:
 Bakirkoy Educ & Res Hosp Psychiat & Neurol Dis, Istanbul, Turkiye

Prevost, J:
 Univ Sydney, Brain & Mind Ctr, Sydney, Australia

Terzi, M:
 CSSS St Jerome, St Jerome, PQ, Canada

Gerlach, O:
 19 Mayis Univ, Fac Med, Samsun, Turkiye

 Zuyderland Med Ctr, Acad MS Ctr Zuyd, Dept Neurol, Sittard Geleen, Netherlands

Macdonell, R:
 Maastricht Univ, Med Ctr, Sch Mental Hlth & Neurosci, Dept Neurol, Maastricht, Netherlands

Sa, MJ:
 Austin Hlth, Melbourne, Australia

 Ctr Hosp Univ Sao Joao, Dept Neurol, Porto, Portugal

Spitaleri, D:
 Inst Invest Inovacao & Desenvolvimento Fernando Pe, FP I3ID, Porto, Portugal

Laureys, G:
 Azienda Osped Rilievo Nazl San Giuseppe Moscati Av, Avellino, Italy

Van Pesch, V:
 Univ Hosp Ghent, Dept Neurol, B-9000 Ghent, Belgium

 Clin Univ St Luc, Dept Neurol, Brussels, Belgium

John, N:
 Catholic Univ Louvain, Louvain La Neuve, Belgium

 Monash Univ, Sch Clin Sci, Dept Med, Melbourne, Australia

Cartechini, E:
 Monash Hlth, Dept Neurol, Clayton, Australia

Gouider, R:
 AST Macerata, Neurol Unit, PO Unico Macerata, Macerata, Italy

 Razi Univ Hosp, Clin Invest Ctr Neurosci & Mental Hlth, Dept Neurol, LR 18SP03, Tunis, Tunisia

Maimone, D:
 Univ Tunis El Manar, Fac Med Tunis, Tunis, Tunisia

:
 Azienda Osped Emergenza Cannizzaro, Ctr Sclerosi Multipla, UOC Neurol, Catania, Italy

Hodgkinson, S:
 Hosp Badalona Germans Trias & Pujol, Dept Neurosci, Badalona, Spain

 UNSW, Dept Med, Sydney, Australia

Slee, M:
 Ingham Inst, Immune Tolerance Lab, Sydney, NSW, Australia

Mccombe, P:
 UNSW, Dept Med, Sydney, Australia

Garber, J:
 Flinders Univ Australia, Coll Med & Publ Hlth, Adelaide, Australia

Sanchez-Menoyo, JL:
 Univ Queensland, Dept Neurol, Brisbane, Qld, Australia

 Westmead Hosp, Dept Neurol, Sydney 2145, Australia

Al-Asmi, A:
 Hosp Galdakao Usansolo, Dept Neurol, Galdakao 48960, Bizkaia, Spain

Kermode, AG:
 Biocruces Bizkaia Hlth Res Inst, Baracaldo, Spain

 Sultan Qaboos Univ, Coll Med & Hlth Sci, Muscat, Al Khodh, Oman

 Univ Western Australia, Perron Inst Neurol & Translat Sci, Nedlands, Australia

 Murdoch Univ, Ctr Mol Med & Innovat Therapeut, Perth, WA, Australia

Lapointe, E:
 Murdoch Univ, Inst Immunol & Infect Dis, Perth, WA, Australia

Shaygannejad, V:
 Univ Western Australia, Sir Charles Gairdner Hosp, Nedlands, WA 6009, Australia

Van Wijmeersch, B:
 Ctr Hosp Univ Sherbrooke, Div Neurol, Med, Sherbrooke, PQ, Canada

 Isfahan Univ Med Sci, Esfahan, Iran

Willekens, B:
 Univ MS Ctr, Hasselt Pelt, Belgium

 Pelt & Hasselt University, Noorderhart Rehabil & MS, Hasselt, Belgium

 Antwerp Univ Hosp, Dept Neurol, Edegem, Belgium

Castillo-Triviño, T:
 Univ Antwerp, Res Grp Translat Neurosci, Fac Med & Hlth Sci, Antwerp, Belgium

Taylor, B:
 Univ Antwerp, Fac Med & Hlth Sci, Lab Expt Hematol, Antwerp, Belgium

 Hosp Univ Donostia, San Sebastian, Spain

Mathey, G:
 Royal Hobart Hosp, Hobart, Australia

 Univ Tasmania, Menzies Inst Med Res, Hobart, Australia

Le Page, E:
 Nancy Univ Hosp, Dept Neurol, Nancy, France

De Seze, J:
 Univ Lorraine, APEMAC, Nancy, France

 INSERM, CIC1414, Rennes, France

Ruet, A:
 CHU Strasbourg, Dept Neurol, Strasbourg, France

Clavelou, P:
 INSERM 1434, Strasbourg, France

 Univ Hosp Bordeaux, Dept Neurol, Bordeaux, France

Berger, E:
 CHU Clermont Ferrand, Dept Neurol, F-63003 Clermont Ferrand, France

Zephir, H:
 Univ Clermont Auvergne, INSERM, Neurodol, Clermont Ferrand, France

Kwiatkowski, A:
 CHU Besancon, Serv Neurol, Besancon, France

Pelletier, J:
 Univ Lille, CHU Lille, CRCSEP Lille, Lille, France

Moreau, T:
 Univ catholique Lille, Dept Neurol, GHICL, Lille, France

Labauge, P:
 Aix Marseille Univ, Hop Timone, APHM, Pole Neurosci Clin, Marseille, France

Ciron, J:
 CHU Dijon, Dept Neurol, Dijon, France

 Montpellier Univ Hosp, Neurol Dept, Montpellier, France

Lebrun-Frenay, C:
 CHU Toulouse, Dept Neurol, Toulouse, France

Papeix, C:
 Univ Toulouse, CNRS, INSERM, Toulouse, France

Defer, G:
 Univ Nice Cote Azur, CRCSEP, Serv Neurol, Nice, France

Laplaud, DA:
 Fdn Rotschild, Dept Neurol, F-75005 Paris, France

Thouvenot, E:
 Caen Univ Hosp, Dept Neurol, Caen, France

 Nantes Univ, CHU Nantes, INSERM,CIC INSERM 1413, Ctr Res Transplantat & Translat Immunol,UMR 1064, F-44000 Nantes, France

Stankoff, B:
 Univ Hosp Nimes, Dept Neurol, Nimes, France

Maillart, E:
 Univ Montpellier, Inserm, CESP, Montpellier, France

Al-Khedr, A:
 Sorbonne Univ, UPMC Univ Paris UMR S 1127 06, Hop Pitie Salpetriere,Inserm U1127,CNRS UMR 7225, AP HP,Inst Cerveau & Moelle Epiniere ICM,Dept Gen, F-75000 Paris, France

Bourre, B:
 Hop La Pitie Salpetriere, Dept Neurol, Paris, France

Casez, O:
 CHU Amiens, Dept Neurol, F-80000 Amiens, France

Dos Santos, A:
 CHU Rouen, Dept Neurol, F-76000 Rouen, France

Camdessanche, JP:
 Univ Grenoble Alpes, Grenoble Alpes Univ Hosp, Dept Neurol,CHU Grenoble Alpes, Neurol MS Clin Grenoble,La Tronche T RAIG,TIMC IMA, F-38700 Grenoble, France

Hankiewicz, K:
 CHU La Mil, Hop Jean Bernard, Dept Neurol, F-86000 Poitiers, France

Wahab, A:
 CHU St Etienne, Dept Neurol, St Etienne, France

Cabre, P:
 Ctr Hosp St Denis, Dept Neurol, Hop Pierre Delafontaine, F-93200 St Denis, France

Heinzlef, O:
 Hop Henri Mondor, APHP, Dept Neurol, F-94000 Creteil, France

Pottier, C:
 CHU Martinique, Dept Neurol, Fort De France, Martinique, France

Moulin, S:
 Hop Poissy St Germain En Laye, Poissy, France

Magy, L:
 Hop Rene Dubos, Dept Neurol, CH Pontoise, Pontoise, France

Labeyrie, C:
 CHU Reims, CRC SEP, Dept Neurol, F-51092 Reims, France

Doghri, I:
 CHU Limoges, Hop Dupuytren, Dept Neurol, F-87000 Limoges, France

Vukusic, S:
 CHU Bicetre, Dept Neurol, F-94275 Le Kremlin Bicetre, France

 CHU Tours, CRC SEP, Hop Bretonneau, F-37000 Tours, France

 Hosp Civils Lyon, Serv Neurol sclerose plaques pathol myeline & Neur, Lyon, France

 Ctr Rech Neurosci Lyon, Observ Francais Sclerose Plaques, INSERM 1028, Lyon, France

Kalincik, T:
 Royal Melbourne Hosp, Neuroimmunol Ctr, Dept Neurol, L7 635 Elizabeth St, Melbourne, Vic 3000, Australia

 Univ Melbourne, Dept Med, CORE, Melbourne, Australia

Univ Lyon, Lyon, France
Eugene Devic EDMUS Fdn Multiple Sclerosis, Lyon, France
ISSN: 11727047





CNS Drugs
Editorial
Adis International Ltd., 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND, Reino Unido
Tipo de documento: Article
Volumen: 40 Número: 7
Páginas: 1011-1025
WOS Id: 001731960400001
ID de PubMed: 41935174
imagen Green Submitted, hybrid

MÉTRICAS